307 related articles for article (PubMed ID: 35463360)
1. Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.
Mahfoudhi E; Ricordel C; Lecuyer G; Mouric C; Lena H; Pedeux R
Front Oncol; 2022; 12():853501. PubMed ID: 35463360
[TBL] [Abstract][Full Text] [Related]
2. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
[TBL] [Abstract][Full Text] [Related]
3. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
4. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
5. Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.
Wu L; Ke L; Zhang Z; Yu J; Meng X
Front Oncol; 2020; 10():602762. PubMed ID: 33392095
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
7. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
Liao BC; Lin CC; Lee JH; Yang JC
J Biomed Sci; 2016 Dec; 23(1):86. PubMed ID: 27912760
[TBL] [Abstract][Full Text] [Related]
8. The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
Laface C; Maselli FM; Santoro AN; Iaia ML; Ambrogio F; Laterza M; Guarini C; De Santis P; Perrone M; Fedele P
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376053
[TBL] [Abstract][Full Text] [Related]
9.
Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T
Mol Cancer Ther; 2019 Jan; 18(1):112-126. PubMed ID: 30322949
[TBL] [Abstract][Full Text] [Related]
10. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
Soejima K; Yasuda H; Hirano T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
[TBL] [Abstract][Full Text] [Related]
12. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).
Mountzios G
Ann Transl Med; 2018 Apr; 6(8):140. PubMed ID: 29862229
[TBL] [Abstract][Full Text] [Related]
13. Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling.
Yu D; Zhao W; Vallega KA; Sun SY
Lung Cancer (Auckl); 2021; 12():1-10. PubMed ID: 33574724
[TBL] [Abstract][Full Text] [Related]
14. HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.
Watanabe S; Goto Y; Yasuda H; Kohno T; Motoi N; Ohe Y; Nishikawa H; Kobayashi SS; Kuwano K; Togashi Y
Thorac Cancer; 2021 Mar; 12(5):631-642. PubMed ID: 33471376
[TBL] [Abstract][Full Text] [Related]
15. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
[TBL] [Abstract][Full Text] [Related]
16. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
[TBL] [Abstract][Full Text] [Related]
17. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.
Hirano T; Yasuda H; Tani T; Hamamoto J; Oashi A; Ishioka K; Arai D; Nukaga S; Miyawaki M; Kawada I; Naoki K; Costa DB; Kobayashi SS; Betsuyaku T; Soejima K
Oncotarget; 2015 Nov; 6(36):38789-803. PubMed ID: 26515464
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
Bollinger MK; Agnew AS; Mascara GP
J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
[TBL] [Abstract][Full Text] [Related]
19. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Pirker R
Curr Opin Oncol; 2016 Mar; 28(2):115-21. PubMed ID: 26720671
[TBL] [Abstract][Full Text] [Related]
20. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]